Amgen bellies back up to the M&A table for another biotech buyout, this time with a $2.5B deal for an antibody player focused on PSMA

Five months after Amgen CEO Bob Bradway stepped up to the M&A table and acquired Five Prime for $1.9 billion, following up with the smaller Rodeo acquisition, he’s gone back in for another biotech buyout. This time around, Amgen is paying $900 million cash while committing up to $1.6 billion…

...

Click to view original post